Preclinical Evaluation Of Vaccines And Antivirals In RSV Challenge SCID Mouse Models

Currently, there are no targeted treatments available for human respiratory syncytial virus (hRSV) infection beyond supportive care aimed at alleviating symptoms. However, the development of effective antiviral drugs and RSV vaccines is expected to play a pivotal role in reducing the global burden of RSV-related illness. Ongoing research, frequently published in leading scientific journals, has energized both large and emerging pharmaceutical and biotechnology companies to accelerate efforts in developing RSV therapeutics. A major challenge in this process is the lack of clinically relevant rodent models, which limits the progress of preclinical vaccine development.

Before advancing to clinical trials, comprehensive pharmacological, safety, and toxicology studies must be conducted to ensure vaccine safety and efficacy. Aragen addresses these challenges by offering IND-enabling preclinical RSV development services, including optimized study designs, validated animal models, and a suite of in vivo and in vitro assays to confirm immune response. Our scientists are dedicated to evaluating the identity, purity, safety, and potency of vaccine and antiviral candidates.

This white paper highlights several case studies conducted in clinically relevant mouse and rat models, including SCID mice, which have been used over several years in both in-house and client-sponsored studies. These studies have generated critical data for the effective screening of RSV therapeutics. Aragen remains committed to advancing RSV drug development by delivering trusted, high-quality preclinical services in this high-impact area of infectious disease research.